The deal is a non-exclusive agreement and the companies were selected through an international bidding process. The arrangement includes the transfer of technology dealing with the manufacture, testing, packaging, storage and handling of the drug's active ingredient. The drug is a second line antiretroviral for patients who have developed a resistance to more common drugs. Peter Dolan, the chief executive of BMS, said the company has taken a broad-based approach to addressing the Aids crisis, which included providing Aids medicines at no-profit prices.
South African and Indian firms win aids drug license
Aspen Pharmacare, South Africa, and Emcure Pharmaceuticals, India, have won a royalty-free licence agreement for the generic of Bristol-Myers Squibb's (BMS) antiretroviral drug Atazanavir, which earned BMS $696 million in sales in the US last year. Atazanavir is known as Reyataz in the US.
May 31, 2007
Machinery Basics
New ebook focused on cartoning equipment
Read about the various types of cartoning equipment, how to select the right one, and common pitfalls to avoid. Plus, read equipment advice from CPGs for ultimate cartoning success.
Read More
